Blinded sample size re-estimation in equivalence testing by Glimm, Ekkehard et al.
Blinded sample size re-estimation in equivalence
testing
Ekkehard Glimm1, Lillian Yau2, and Heike Woehling2
1Novartis Pharma AG, Basel, Switzerland
2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany
August 14, 2019
Abstract
This paper investigates type I error violations that occur when
blinded sample size reviews are applied in equivalence testing. We give
a derivation which explains why such violations are more pronounced
in equivalence testing than in the case of superiority testing. In addi-
tion, the amount of type I error inflation is quantified by simulation as
well as by some theoretical considerations. Non-negligible type I error
violations arise when blinded interim re-assessments of sample sizes are
performed particularly if sample sizes are small, but within the range
of what is practically relevant.
Keywords: bioequivalence, biosimilar, non-inferiority, sample size re-
estimation, TOST, type I error control
1 Introduction
Discussions on sample sizes re-estimation (SSR) have appeared in statistical
literature as early as the 1940’s [1]. Since then a growing body of literature
has emerged. For the two-sample t-test of a new treatment versus a control,
methods based on estimators of the sample variance which can be calculated
without unblinding the group affiliation of the observations available at an
interim analysis have been introduced [2, 3]. The simplest of these is the
“total variance estimate” which is the usual one-sample variance estimate
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calculated from treating all observations as if they were from only one treat-
ment group. Although it has been shown that under this approach the type
I error is not strictly controlled [4, 5], in the case of superiority testing, the
type I error violations are extremely small and even then occur only in small
samples. From an applications perspective, these investigations therefore re-
inforce the recommendations made by [2] and [3]. However, in the case of
non-inferiority (NI) testing, and thus also in equivalence (EQ) testing, this
inflation can be larger [5, 6, 7, 8]. In this paper we take a closer look at the
non-trivial type I error inflation in NI and EQ testing and the factors that
impact it. We also provide practical recommendations to clinicians and data
analysts who wish to implement a blinded SSR in their equivalence studies.
We base our discussion on a design with two stages and two treatment
groups. Stage 1 consists of subjects whose data are used for estimating the
total variance; stage 2 consists of subjects who are additionally recruited
after the interim. In certain cases, no additional subjects are needed and
stage 2 does not have any subjects. An important assumption is that beside
the total sample size, other elements of the study design do not change after
the interim.
We use the following notations in our discussions. For treatment group
j, j = {1, 2}:
n˜j = stage 1 sample size
mj = stage 2 sample size
nj = n˜j +mj = realized total sample size
nj,Min = planned minimum total sample size
nj,Max = planned maximum total sample size
We assume nj,Max ≥ nj,Min ≥ n˜j .
In Section 2, we derive a decomposition of the total variance observed at
the time of blinded SSR to demonstrate how type I error inflation arises in
NI and EQ tests. Section 3 provides a brief introduction to the two one-sided
tests (TOST) approach to EQ testings. Section 4 outlines the simulation
settings and presents the results. Section 5 discusses how different factors
impact the type I error. In Section 6 we summarize our findings.
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2 Type I error violation in non-inferiority testing
A common strategy for EQ testing is the TOST approach [9]. This uses two
NI tests. For this reason we start by looking at the latter.
Assume that we want to test H0 : δ ≥ δ0 versus HA : δ < δ0 at level α on
independent normal observations yij from N(µj , σ
2) in two groups j = 1, 2
and i = 1, . . . nj . Let δ = µ1 − µ2, and y¯j be the mean of the observations
in group j. Without loss of generality, assume furthermore that δ0 > 0. We
proceed with the “total variance”
σˆ2T =
Q
n˜∗ − 1 =
1
n˜∗ − 1
2∑
j=1
n˜j∑
i=1
(yij − y¯)2 , (1)
where n˜∗ = n˜1 + n˜2, and y¯ = n˜1y¯1+n˜2y¯2n˜∗ is the mean across the two groups.
To calculate E(σˆ2T ), we decompose Q into Q1 and Q2, where
Q1 =
2∑
j=1
n˜j∑
i=1
(yij − y¯j)2
Q2 =
2∑
j=1
n˜j (y¯j − y¯)2 .
It follows that Q = Q1 + Q2. By Cochran’s theorem, Q1 and Q2 are
stochastically independent with distributions Q1 ∼ σ2χ2(n˜∗ − 2) and Q2 ∼
σ2χ2(1; n˜1n˜2n˜∗
δ2
σ2
), which is a non-central χ2 distribution. Hence,
E(Q) = E(Q1) + E(Q2) = (n˜∗ − 2)σ2 +
(
1 +
n˜1n˜2
n˜∗
δ2
σ2
)
σ2,
and
E(σˆ2T ) =
1
n˜∗ − 1E(Q) = σ
2
(
1 +
n˜1n˜2
n˜∗(n˜∗ − 1)
δ2
σ2
)
. (2)
To illustrate how type I error inflation may arise, consider the following
SSR rule:
1. If σˆ2T is large, i.e. σˆ
2
T > c for some preselected threshold c > 0, we
recruit mj , j = 1, 2, additional subjects.
2. If σˆ2T is small, i.e. σˆ
2
T ≤ c, we do not recruit additional subjects, but
stop and test right away with the n = n1 + n2 = n˜1 + n˜2 subjects we
have.
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If the true δ > 0, we can see from Equation (2) that a small value of
σˆ2T provides evidence against H0, because E(σˆ
2
T ) does not only depend on
the variance, but also on the squared true mean difference between the two
groups. Hence, the rule above stops recruiting and uses the data obtained up
to the interim analysis undiluted by additional observations if it happened
to be in favor of HA, but dilutes this evidence by recruiting more subjects
if the data obtained up to the interim analysis shows evidence in favor of
H0. It is clear that this must inflate the type I error of the entire strategy.
The same is true for other blinded sample size re-estimation rules where the
final total sample size is an increasing function of σˆ2T . On the other hand,
if the sample size re-estimation rule were a decreasing function of σˆ2T , then
we would have α deflation.
Two remarks are important. Firstly, from Equation (2) we can see that
the inflation is primarily associated with the shifted hypothesis H0 : δ ≥
δ0 > 0. If δ0 = 0, then at the point of δ = δ0, σˆ
2
T is an unbiased estimate of
σ2. Regarding type I error control, what matters is the behavior of the test
at δ = δ0. Hence, the issue investigated here does not occur with superiority
testing where H0 : δ = δ0 = 0. Intuitively, a large σˆ
2
T does not provide
evidence in favor of, or against, the superiority hypothesis, because a large
observed σˆ2T can equally likely arise from δ or −δ being true. With the
shifted δ = δ0 > 0, however, a large value of σˆ
2
T will much more likely occur
with a value of y¯1− y¯2 > δ than with y¯1− y¯2 < −δ. We note in passing that
simply subtracting a constant, i.e. a hypothetical true difference, from the
total variance cannot influence this issue.
Secondly, the statements we have made here are qualitative: There will
be a type I error inflation, but its magnitude depends on many things: the
effect size δ0/σ, the stage 1 sample size, the range of possible values of
the stage 2 sample size, the actual small sample properties of a test using a
test statistic which is only asymptotically Normal, and the like. Equivalence
testing with TOST is a case in point. If the equivalence margin is symmetric
(i.e. δ0 = δup = −δlow), then exactly the same mechanisms are at work at
both the upper and the lower end of the equivalence range, and both one-
sided level-α-tests are subject to type I error inflation with the sample size
review strategy described above. The actual probability of rejection in the
TOST, however, is also subject to the inherent conservatism of the TOST
strategy which arises from the fact that there is a positive probability of not
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rejecting H01 : δ ≤ −δ0 when in fact H02 : δ ≥ δ0 is true. This conservatism
of course remains and may counteract against the liberality caused by the
phenomenon we discussed.
An analytical calculation of the exact type I error rate is possible, how-
ever, given the many factors at play, the derivation is often algebraically
consuming. In Appendix A, we discuss the quantification of the type I error
inflation in a specific case. For general discussion, we use simulation studies.
3 Equivalence testing and TOST
In the TOST approach to equivalence testing, two hypotheses are tested
simultaneously:
H01 : δ ≤ δlow vs. HA1 : δ > δlow, and
H02 : δ ≥ δup vs. HA2 : δ < δup,
where δlow and δup are the lower and the upper equivalence margins. To
claim equivalence, both null hypotheses must be rejected simultaneously
at level α. Using the same notations as in Section 2, and with the given
reference range (δlow, δup), we reject the null hypothesis of non-equivalence
H0 = H01 ∪H02 if√
n1n2
n1 + n2
· d− δlow
s
> t1−α(n1 + n2 − 2),
and √
n1n2
n1 + n2
· d− δup
s
< tα(n1 + n2 − 2),
where d = y¯1 − y¯2 and
s2 =
1
n1 + n2 − 2
2∑
i=1
ni∑
j=1
(yij − y¯i)2.
This decision rule can also be described via a (1 − 2α) level confidence
interval (CI) for δ. If this CI is completely contained within (δlow, δup), then
equivalence between the two groups is declared at level α.
In Figure 1 we distinguish four possible outcomes with regard to the
rejection of the two null hypotheses, and illustrates them in terms of the CI
for δ. Per these definitions, Case 1 is where equivalence is established.
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Figure 1: Four possible outcomes of a TOST
Consider an EQ test using TOST where H02 is true. Case 1 represents a
false rejection and establishes an equivalence incorrectly, i.e. a type I error.
Although Case 2 is the least desirable outcome, it makes TOST conservative:
it falsely rejects H02, but also falsely does not reject H01, thus comes to the
correct conclusion that the equivalence cannot be established, even though
the reasoning is wrong. Case 3 is the most desired outcome since it correctly
supports non-rejection of H02 but rejection of H01. Case 4 does not reject
either null hypothesis, therefore, reaches the correct decision of not rejecting
H02.
For NI testing where H02 is true, Case 1 and Case 2 together represent
false rejection of the null hypothesis.
4 Simulation studies
We investigate the impact of stage 1 sample size (n˜j), stage 2 sample size
(mj), and effect size on type I error inflation in a blinded SSR for EQ
testing using simulation studies. Without loss of generality, we set σ to 1,
and assume symmetric equivalence margins where δup = δ0 = −δlow; hence,
in subsequent discussions δ0 and effect size δ0/σ are numerically the same.
The sample sizes for the two groups are assumed the same at every stage,
so the subscript j is dropped in the discussion. We follow this strategy:
before the start of the study, define n˜, nMin, and nMax where n˜ ≤ nMin ≤
nMax. A blinded sample size re-assessment is conducted when data from n˜
subjects per group become available.
4.1 The SSR rule
The total sample size needed in each group, denoted Nˆ , in order to reject
H01 and H02 for a desired power 1 − β is calculated based on σˆ2T . Nˆ is
compared to nMin and nMax such that
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(1) if Nˆ ≤ nMin, then additional m = nMin− n˜ subjects are recruited per
group in the second stage;
(2) if Nˆ > nMin, then additional m = min(Nˆ , nMax) − n˜ subjects are
recruited in the second stage.
Hypotheses H01 and H02 are tested with n = n˜+m total subjects per group
at the end of the study.
4.2 Simulation settings
All of the simulations use α = 5% and β = 10%. Table 1 summarizes the
other conditions:
Table 1: Simulation settings
Parameter Values
n˜ 10, 15, 20, 25, 30, 40, 50, 60
nmin/n˜ 1, 1.2, 1.4, 1.6, 1.8, 2
nmax/n˜ 2, 2.5, 3, 3.5, 4, infinity
δ0/σ = δ0 0.05 to 1.5 at 0.05 interval
Take n˜ = 20, nMin/n˜ = 1.4 (or equivalently nMin = 20× 1.4 = 28), and
nMax/n˜ = 2 (or nMax = 20 × 2 = 40) as an example. Our strategy says
that the interim analysis is to be conducted when data from 20 subjects per
group become available. Based on the total variance estimate σˆ2T , if the total
sample size Nˆ is determined to be no more than 28 subjects per group, then
additional m = 8 subjects per group will be recruited in the second stage,
making it total of n = nMin = 28. On the other hand, if the re-assessed
sample size Nˆ turned out to be larger than 28, then m = min(Nˆ , 40) − 20
subjects per group are to be recruited for the second stage.
One million simulations are performed for each combination of the pa-
rameter values in Table 1. Normally distributed data are generated for the
two groups with a mean difference of δ0. This corresponds to a true H02.
In each simulated sample t-test is conducted between the two groups. The
percentages of each of the four cases (as illustrated in Figure 1) are summa-
rized.
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4.3 A note on sample size calculation
For each simulated sample, the total sample size Nˆ is calculated from the
stage 1 data by assuming a common population variance σ2 estimated by
σˆ2T . Ideally Nˆ should be calculated using non-central t-distribution as out-
lined in [9]. However, this would require iterative approximation of degrees
of freedom for each single simulation. Furthermore, we focus on type I error
inflation which ultimately depends on the sample size formula only via Nˆ .
For this purpose, it is essentially irrelevant if the t- or the simpler z-formula
is used. In both cases, type I error inflations follow identical patterns. There-
fore, we use the usual sample size formula based on the asymptotic normal
distribution:
Nˆ =
2(Z1−β/2 + Z1−α)2
((δ0 −D)/σˆT )2 , (3)
assuming 1:1 randomization ratio. Since we are blinded at interim analysis,
we do not have an estimate for δ; a value D must be assumed. In NI and EQ
testing, it is common to assume that there is no difference between groups
when doing power and sample size calculations. We follow this practice and
assume D = 0.
Although Equation (3) tends to give smaller sample sizes, its dependency
on δ0/σT is the same as its t-distribution based counterpart. Other com-
ponents such as n˜, m, nMin, nMax, etc., only impact the amount of the
inflation. As Appendix A shows, a different sample size determination rule
may dictate a completely different pattern of α behavior. Since Equation
(3) and its t-distribution counterpart are implemented in many statistical
software for power and sample size calculations, for example NCSS PASS or
R package PowerTOST [10, 11], we make this our main objective of investi-
gation.
4.4 Results
We first present a benchmark example. Figure 2 shows the observed type I
error rate for NI and EQ testings for the setting where n˜ = 15, nMin = 18,
and nMax = 30. What this rule says is that we conduct the interim when
there are 15 subjects in each group; if the observed total variance σˆ2T is
small enough such that we will only need up to a total of 18 subjects per
group in order to reject H0 with 90% power at 5% nominal α level, then we
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will recruit 3 additional subjects in each group; otherwise, we will recruit
however many subjects needed but not exceeding 30.
Figure 2: Percent Case 1 or Case 2
In Figure 2 there are two red dashed lines on each panel representing the
95% CI around 5% in one million simulations. Any values within these two
dashed lines can be attributed to random variation. In Panel A, percentages
of Case 1 are plotted against the effect size. Recall a Case 1 is where the
CI for the difference between the two groups is completely contained within
the equivalence margins. Its probability under H0 is the type I error rate for
an EQ testing. When effect size is at or below 0.30, the standard deviation
σ, which is set to be 1 for all the simulations, is much too large for δ0. The
interim total variance σˆ2T , serving as an approximation for σ
2, will tend to be
very large in this area as well. Therefore, even with the largest sample size
allowed according to our SSR rule, nearly no CI for the difference between
the two groups are narrow enough to be within (−δ0, δ0). Hence, no type I
error is committed under the EQ hypothesis.
However, this is not to say that H02 : δ ≥ δ0 is correctly not rejected.
Panel B of Figure 2 shows the percent of Case 2 against effect size. Recall a
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Case 2 is where the lower end of the confidence interval is below the lower
margin. The probability of false rejection of H02 starts out at 5% and drops
below that at effect size equals to 0.30 for exactly the reason that σ is too
large relative to δ0 in this area. If H02 is indeed falsely rejected, the chances
are higher that they are Case 2 rather than Case 1.
As δ0 becomes larger the CI for the group difference is becoming narrower
given the same SSR rule. This in turn shows in Panel A such that the
percentage of Case 1 is increasing sharply between effect size 0.30 and 0.5;
at the same time, percentage of Case 2 starts to decrease, and reaching 0%
at 0.55 just when percent Case 1 reaches 5%. If we look at Panel C, we see
the two cases add up nicely to about 5% or exceeding that where there is
inflation. In fact, Panel C (or Panel D for a close-up) are the observed α in
a NI test against H02 with the given SSR rule. For both NI and EQ testing,
the α inflation happens between effect size 0.70 and 1.25 with a peak at
0.95.
The patterns in Figure 2 are consistent in all of the settings we examined.
The difference is in where the peak α occurs, and how much it inflates to.
Figure 3 summarizes the percent of Case 1 in form of heatmaps where a
darker shade indicates a larger α value. In addition, we see how n˜, nMin,
and nMax influence α inflation from these plots. Four stage 1 sample sizes,
n˜ = 10, 15, 20, and 30, are selected for display. They are in columns from
left to right. The rows in Figure 3 represent nMax in terms of the ratio
nMax/n˜. The selected values are nMax/n˜ = 2, 3, 4, and infinity. Within
each of the 16 heatmaps, the x-axis represents the effect size from 0.05 to
1.5; the y-axis represents the nMin in terms of the ratio nMin/n˜. Note that
in our simulations we have chosen discrete nMin/n˜, and the y-axis is not
truly continuous. The benchmark example we have shown in Figure 2 is
highlighted with a red rectangle.
The graphs show that inflations of type I errors occur at δ0/σ between
0.8 and 1.5, and that they are more severe with small stage 1 sample sizes
and when nMin = n˜.
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Figure 3: α and inflation for stage 1 sample sizes n˜ (or s1ss) = 10, 15, 20,
30.
5 Discussion
5.1 Stage 1 sample size and α inflation
In Figure 3 we see a consistent decrease of α inflation as n˜ increases. This
is related to the precision in the estimate of V ar(σˆ2T ). Given Equation (1),
we derive
V ar(σˆ2T ) =
2σ2
(2n˜− 1)2
[
n˜(2 + δ2)− 1] = O(δ2
n˜
)
. (4)
With fixed δ, V ar(σˆ2T ) decreases as n˜ increases. The sample size formula in
Equation (3) which is investigated in the simulations depends on the stage 1
sample size only via σˆ2T . The more variation we see in σˆ
2
T the more variable
second stage sample sizes will be. In turn this variability in stage 2 sample
sizes induces α inflation.
To have a closer look, we investigate how the percentage of rejections
depends on σˆ2T for an exemplary case with δ0/σ = 1 between a fixed design
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and 2-stage design with SSR. Results are from 105 simulations assuming
H02 : δ = δ0 is true. First, the responses from a total of 30 subjects, 15 per
group, are generated. For the fixed design, ordinary t-tests are conducted
from these 30 subjects. For the 2-stage design with SSR, the total variance
σˆ2T is calculated from the 30 subjects, and a stage 2 sample size m, where
0 ≤ m < ∞, is determined according to Equation (3) with α = 5% and
β = 10%. Data from the two stages are then combined to conduct the t-test
across both stages.
Figure 4: Percent false rejections in intervals of total variance σˆ2T , δ0/σ = 1.
Figure 4 shows the percent of rejections of H02 is related to the distri-
bution of values of σˆ2T for both the fixed design (black bars) and the 2-stage
design (gray bars). The height of the bars shows the percentage of rejections
which occur in intervals of observed σˆ2T values. The first of these intervals
contains all values of σˆ2T which are so small that m = 0. In this example,
this requires that σˆ2T ≤ 0.693, and includes 2.3% of all simulations. When
this happens, the fixed and the 2-stage design are the same. 46% of the 2.3%
where σˆ2T ≤ 0.693 (i.e. 1.06% of all cases) in the simulation are rejections of
H02. The remaining cases (where σˆ
2
T > 0.693 and hence m > 0) are binned
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into 9 equally sized intervals, i.e. each interval contains 9,771 simulation
results.
The plot supports the results from Section 2 which show that small
values of σ2T are providing information against H02. As σ
2
T gets larger, the
percent rejections by the fixed design are decreasing towards 0: the weighted
average across all intervals is of course α = 5%. For the 2-stage design, the
rejection rate is the same as the fixed design when σˆ2T ≤ 0.693 (because
m = 0 there), but as σˆ2T increases, they diverge from each other. While the
second (from the left) gray bar is even lower than its black counterpart, from
the 4th pair onwards the 2-stage rejection rates are higher. This reflects the
fact that additional stage 2 data helps to overcome the dampening effect of
large σ2T on rejection probability. Overall, the weighted average of the gray
bars becomes 5.83% demonstrating the type I error inflation.
The graph also shows that while general tendencies are predictable—such
that rejection rates must decrease; the two sets of rates diverge as we move to
the right; the gray bars on average are higher than the black bars especially
on the right of the plot, etc.—some peculiarities of the specific sample size
formula in Equation (3) also play a role. In this case, for example, the
largest total sample size requested by any of the simulation runs is 74. This
shows that, although we have not put any “formal” upper limit on stage 2
sample size, the formula is such that stage 2 sample sizes which completely
dominate the stage 1 data simply do not occur. If the sample size formula
were such that huge stage 2 sample sizes would occur frequently enough,
the red bars would approach a height of 5% as we move to the right in the
plot. The fact that the 2-stage design has a slightly lower rejection rate in
the second lowest interval of σ2T can be explained as such.
In the case when n˜ is large, the observed range for σˆ2T is much smaller.
The behavior of the observed α values resembles a fixed design more closely.
The inflation of α is less severe.
As this reasoning shows, the variability of σˆ2T in the simulations is a
good indicator of the SSR method’s ability to react to different stage 1 data
situations in favor of rejection of H0. In contrast, when σˆ
2
T is very precise,
the total (and the second stage) sample size is almost always the same from
simulation to simulation, and we are led to always need the same overall
sample size. This resembles a fixed stage design where the total sample
size is predetermined and a mid-way look of the data does not change any
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element of the study design, hence, having no impact on α.
Therefore, one obvious remedy in reducing α inflation is to increase the
stage 1 sample size. However, in practice stage 1 sample size has to be
reasonably small so that operationally there is enough time for an interim
analysis to be carried out. Alternatively, we could reduce the variability of
the stage 2 sample size by imposing a nMin or a nMax on the overall sample
size. Of course, this is against the original motivation for the sample size
review whose intent is to be able to modify the final actual sample size as
freely as possible.
5.2 Effect size and α inflation
From Equations (1) and (3), with σ = 1, D = 0, and under H02 : δ = δ0, we
derive the expected value of the total sample size for each group
E(Nˆ) = 2(Z1−β/2 + Z1−α)2
(
1
δ20
+
n˜
4n˜− 2
)
, (5)
and its standard deviation
SD(Nˆ) = 2(Z1−β/2 + Z1−α)2 ×
SD(σˆ2T )
δ20
= O
(
1
δ0
· 1√
n˜
)
. (6)
Although both E(Nˆ) and SD(Nˆ) approach infinity as δ0 goes to 0, the
former approaches at a higher rate since
lim
δ0→0
E(Nˆ)
SD(Nˆ)
=
1
δ0
=∞.
For small δ0, stage 2 sample size will always overwhelm stage 1 sample size
if there is no restriction on the overall sample size. In our simulations, when
δ0 = 0.05 the average total sample size required to reject the null hypothesis
with 90% power at 5% nominal α level is close to 9,000 per group. Faced
with such a large average Nˆ , the information carried in stage 1 data are
eclipsed. This again resembles a study with a single stage.
Figure 5 shows the effect size (x-axis) vs. percent of Case 1, or type I
error (y-axis) for an EQ test for all the n˜ we investigate, allowing 0 ≤ m <
∞. At the small end of δ0 regardless of the size of n˜, α is around 5% for the
reason just stated.
However, in reality the upper limit of the total sample size cannot be
left un-capped. When nMin and nMax are predefined, since Nˆ is so large,
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Figure 5: α and inflation when 0 ≤ m <∞.
nMin does not play any role, and nMax is always reached. What is more,
since nMax << ∞, there is almost no power to reject H01, which is false.
This implies Case 2 is the case predominating the false rejection of H02. For
example, Figure 6 gives results for n˜ = 15 and nMin fixed at 30 whereas
nMax is infinity, 60, 38, or 30. As nMax decreases from 60 to 38 and then 30,
the power for rejecting the false H01 decreases, and Case 1’s become Case
2’s. Visually, the effect size where Case 1 rises to the range of 5% shifts from
0.45, to 0.60 and 0.70, respectively.
As the effect size moves away from 0, Nˆ < nMax more and more often,
and the variability in stage 2 sample size increases. Therefore, α starts to
become more than its nominal level for the same reason given in Section 5.1.
At the other end of the spectrum where δ0 is large, Equation (5) gives
us
lim
δ0→∞
Nˆ =
n˜
2n˜− 1
(
Z1−β/2 + Z1−α
)2
,
and
lim
δ0→∞
SD(Nˆ) = 0.
15
Figure 6: Controlling % Case 1 by decreasing nMax. Figure example: n˜ =
15, nMin = 30.
With β = 0.10 and α = 0.05, when n˜ = 1, limδ0→∞ Nˆ = 11; when n˜ gets
larger it converges to 5.5. In any practical setting where n˜ is at least 6, the
stage 1 sample is already sufficient for the desired power. Therefore, any
nMin ≥ n˜ ≥ 6 will have nMin as the final total sample size, and nMax will
not play a role. This is why in Figure 5 where 0 ≤ m < ∞, we can see a
convergence toward 5% for all n˜ at the larger end of δ0.
Before δ0 becomes so large that Nˆ settles toward 5.5, SD(Nˆ) is larger
than 0, which can result in Nˆ that are above nMin but not equal to or
exceeding nMax. To reduce the variation in Nˆ and α inflation, we can set
nMin just high enough to include all foreseeable cases where this lower limit
of Nˆ suffices to reject H0 with desired power at the nominal α level. From
Figure 7 we can see that even with a moderate increase in the mandatory
minimum total sample size, the α inflation reduces sharply.
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Figure 7: Controlling % Case 1 by increasing the mandatory nMin. Figure
example: n˜ = 15, nMax = 30.
5.3 The peak α inflation
As discussed in Section 2, the precise type I error inflation depends on many
factors such as stage 1 sample size, the equivalence margin, the sample size
re-estimation rule which potentially includes upper or lower limits of the
final sample size. It is difficult to give a general, analytical solution to the
upper limit of the α inflation. As can be seen in all the figures, different
versions of the SSR have led to different peaks both in terms of magnitude
and the corresponding δ0 value even with the same stage 1 sample sizes.
Given the results from our simulation, if at the planning stage of a study,
the range of assumed effect sizes falls on the smaller side of the effect size
where peak α would occur, then it is important to impose a nMax, since
it can “postpone” the Case 1 from coming into the picture along the axis
of effect size. It is clear though this solution results in having hardly any
power for establishing the EQ or NI. Moreover, from a practical perspective,
this is probably very rarely a relevant case. Because if it so happens that
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σ2 is much larger in relation to δ0, it is simply hard to establish equivalence
in the first place. In fact, in biosimilar pharmacokinetics studies where
intra-individual variability is too large relative to the regulatory agencies’
pre-defined equivalence range, FDA for example allows an approach where
the reference range are scaled to the variability of the reference product [12].
On the other hand, if the assumed effect size for the study is on the
larger side of where the peak α would occur, it is important to impose a
larger nMin so it can force the convergence to the nominal α level earlier
in terms of effect size. It is obvious that this solution can result in an
overpowered study that is larger than necessary.
Table 2 shows the effect sizes and the peak α for each n˜ in our simulations
where 0 ≤ m < ∞. They can serve as a reference for future planning.
Although Table 2 refers to the type I error rate of an EQ test, for the NI
test, the α are negligibly larger.
Table 2: Peak α and its corresponding effect size
n˜ % Case 1 δ0/σ
10 6.26 1.20
15 5.78 0.95
20 5.63 0.85
25 5.55 0.80
30 5.45 0.75
40 5.34 0.60
50 5.30 0.60
60 5.23 0.55
80 5.18 0.45
6 Summary
We have investigated causes of type I error inflation arising when blinded
sample size reestimation is performed in equivalence trials. In Section 2, we
have given an explanation for why non-trivial type I error inflation can arise
in this situation. The reasoning behind this explanation allows the construc-
tion of blinded sample size estimation rules which emphasize the inflation
(one such rule is investigated in the Appendix). However, from an applied
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perspective, it is more important to understand how this phenomenon im-
pacts sample size re-estimation rules which are used in practice.
To investigate this, we have performed extensive simulations using SSR
outlined in Section 4.1. We have set up the simulations to focus on scenarios
where inflation must be suspected, but that are also practically relevant.
We find that the variation of the stage 2 sample size is a good, but not
the only, indicator of (the magnitude of) type I error inflation. The stage 2
sample size is an increasing function of the total variance estimated at the
interim. Hence, it is more variable when stage 1 is small and when there
are no limits on the minimum and the maximum sample size allowed in
stage 2. When the standardized EQ margin (δ0/σ) is very strict, stage 2
sample size is invariably estimated to be large in general and no inflation
can arise. Conversely, when it is very generous, the stage 2 sample size tends
to be always small and converges to a constant number as the margins tend
towards infinity. Hence, there can also be no inflation. For this and practical
reasons, the focus of our attention is on cases where the equivalence margin
is roughly the same as the standard deviation.
We observe that if stage 2 sample size is not limited by additional re-
strictions, type I error inflations to 6.3% can arise for stage 1 sample sizes
of 10 subjects per group, a small, but not entirely unrealistic number, and
persist (5.2%) for as many as 80 subjects per group in stage 1.
These inflations are reduced when limits are placed on the allowed stage
2 sample sizes. In the range of practically relevant EQ margins, the lower
limit (nMin) is much more important than the upper limit (nMax) here. The
upper limit has an substantial impact on type I error probability only for
values of the EQ margin that are a lot smaller than the standard deviation
of the data.
Our investigation shows that the more similar to a fixed design a study
is, the less α inflation can arise. This points to designing a study with a
narrower range of nMin and nMax. However, we also realize that when an
interim is deemed necessary when planning a study, chances are there are
uncertainties in key assumptions. Not having a lot of flexibility in choosing a
second stage sample size limits the opportunities to rectify these uncertain-
ties, hence, defeats the purpose of having an interim analysis and reduces
the attractiveness of a blinded SSR. For an alternative, one can consider
unblinded SSR for equivalence testing, see for example [13].
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As a recommendation for clinicians and data analysts who wish to in-
corporate a blinded SSR for a NI or EQ study, we suggest:
(1) Choose a reasonably large interim sample size. From our simulations
and recent experiences in planning clinical studies, n˜ should be at least
15.
(2) Allow m ≥ n˜. In other words, impose a minimum cap nMin such that
nMin ≥ 2n˜. If the stage 1 sample size is larger than 30, this can be
relaxed.
(3) Limit the absolute maximum total. Our simulations show that nMax ≤
3n˜ provides reasonable α control.
When all these conditions are satisfied, maximum α can be limited to
within 5.3%. The third recommendation will probably be followed in prac-
tice already to avoid over costly big studies.
A Numerical evaluation of type I error inflation
for NI and EQ testing
Here we aim to demonstrate two points. First, we give a numerical example
of a sample size re-estimation rule where an increased stage 1 sample size
does not imply asymptotic decreasing of α inflation. Second, through this
example we illustrate the do-ability of analytical computation of the exact
α once the components of an SSR rule are defined.
In this example, we assume that no additional subjects are recruited if
the total variance estimate σˆ2T , defined in Equation (1), is less than or equal
to a threshold c∗. When this happens, the study is unblinded, and a final
hypothesis testing is conducted based on d = y¯1− y¯2, the observed difference
between the mean responses in group 1 and group 2 after stage 1–the only
stage, of the trial.
Since σˆ2T =
Q1+Q2
n−1 , we can express this as a boundary c = (n− 1) · c∗ on
Q1 +Q2.
For ease of notation, in this section, let stage 1 sample sizes for the
two groups be n1 and n2 such that n1 = n2, and total stage 1 sample size
n = n1 + n2 = 2n1. Therefore,
√
n1
2 d ∼ N(
√
n1
2 δ, σ
2), and Q2 =
n1
2 d
2.
Consider the test
H02 : δ ≥ δup
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which will be rejected if
tup =
√
n1
2
· d− δup√
Q1
n−2
≤ tα(n− 2).
It follows that P (rejecting H02) = P (tup ≤ tα(n− 2)) can be calculated in
two steps: (1) the probability when Q1 + Q2 ≤ c, and (2) the probability
when Q1 +Q2 > c.
As a numerical example, consider α = 0.05, σ2 = 1, δ = δup = 0.5. We
look at the cases where n1 = 12, 24, 40 and let c = n− 1 + n12 δ2. We first
calculate P
(
tup ≤ tα(n− 2)
∣∣ Q1 +Q2 ≤ c).
In general, for a given Q1 = x, we have
P
(
tup ≤ tα(n− 2)
∣∣ Q1 = x) =
P
(√
n1
2
· (d− δup) ≤ q ·
√
x
n− 2
)
= Φ
(
q ·
√
x
n− 2 −
√
n1
2
(δ − δup)
)
,
where Φ(·) denotes the cdf of N(0, 1), and q = tα(n− 2).
Conditional on a given x with x < c, the joint distribution of rejecting
H02 and Q1 +Q2 ≤ c is given by
P
(
tup ≤ tα(n− 2),
√
n1
2
|d| ≤ √c− x
∣∣∣∣ Q1 = x) =
P
(√
n1
2
· (d− δup) ≤ q ·
√
x
n− 2 ,
√
n1
2
· (d− δup) ≤
√
c− x−
√
n1
2
δup,√
n1
2
· (d− δup) ≥ −
√
c− x−
√
n1
2
δup
)
=
Φ
(
min
(√
c− x−
√
n1
2
δup, q ·
√
x
n− 2
))
− Φ
(
−√c− x−
√
n1
2
δup
)
if q ·
√
x
n−2 > −
√
c− x−√n12 δup and 0 otherwise.
Hence, the joint distribution of rejection of H02 and Q1 +Q2 ≤ c is given
by
P (tup ≤ tα(n− 2), Q1 +Q2 ≤ c) =∫ c∗
x=l∗
{
Φ
(
min
(√
c− x−
√
n1
2
δup, q ·
√
x
n− 2
))
− Φ
(
−√c− x−
√
n1
2
δup
)}
· f(x)dx, (7)
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where f(·) denotes the pdf of χ2(n− 2) and 0 ≤ l∗ < c∗ ≤ c limit the range
of integration in such a way that the integrand is larger than 0. The limits
l∗ and c∗ are those solutions of the two equations
q ·
√
x
n− 2 = −
√
c− x−
√
n1
2
δup (8)
and
q ·
√
x
n− 2 =
√
c− x−
√
n1
2
δup (9)
which fall inside the interval [0, c] (if there are such solutions). If no solution
falls inside the interval [0, c], then l∗ = 0 and c∗ = c, respectively. Equations
(8) and (9) can both be converted into quadratic equations and thus have
closed-form solutions. To find a solution, we first have to check whether the
solutions of the quadratic equations corresponding to (8) or (9) are actually
solutions to (8) or (9), and then check which of these solutions fall into [0, c].
This is a mathematically straightforward, but somewhat tedious process.
The conditional distribution of rejection of H02 given Q1 + Q2 ≤ c is
thus
P (tup ≤ tα(n− 2), Q1 +Q2 ≤ c) · (P (Q1 +Q2 ≤ c))−1 .
Formula (7) can be evaluated numerically (e.g. by SAS CALL QUAD).
Likewise P (Q1 +Q2 ≤ c) is a probability from the non-central χ2-distribution
χ2(n−1; n12 δ2) that is implemented in most statistical software packages like
SAS or R.
In the given numerical example, we have (calculations for n1 = 12, num-
bers in brackets for n1 = 24, 40, respectively)
P (tup ≤ tα(n− 2), Q1 +Q2 ≤ c) = 0.0401(0.0396, 0.0393)
P (Q1 +Q2 ≤ c) = 0.5946(0.5661, 0.5510)
P
(
tup ≤ tα(n− 2)
∣∣ Q1 +Q2 ≤ c) = 0.0401
0.5946
= 0.0674(0.0699, 0.07125).
Now we calculate the probability of rejecting H02 when Q1 + Q2 > c.
If the sample size in both groups is increased in such a way that stage 1
is rendered almost irrelevant. Then, P
(
H02 rejected
∣∣ Q1 +Q2 > c) u 0.05
and hence the type I error probability of this blinded SSR procedure at
δ = δup becomes 0.5946 ·0.0674 + (1−0.5946) ·0.05 = 0.0603(0.0612, 0.0617)
instead of the nominal α = 0.05.
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Up until now, the discussion in this section focuses on NI testing when
there is only one hypothesis, i.e. H02, to be tested. Next we consider EQ
testing where H01 also need to be tested. Compare to NI testing, there is a
decrease of the type I error which arises in the TOST strategy when H02 is
rejected but H01 is not, i.e. Case 2 as defined in Section 3. This feature of
TOST safe-guards the α inflation to some extend.
The joint probability that Q1 + Q2 ≤ c, and both H01 and H02 are
rejected is given by
P (tlow ≥ t1−α(n− 2), tup ≤ tα(n− 2), Q1 +Q2 ≤ c) = (10)
P
(
Z ≥ q∗(Q1), Z ≤ q
√
Q1
n− 2 ,
Z ∈
[
−√c− x−
√
n1
2
δup,
√
c− x−
√
n1
2
δup
])
=∫ c∗
x=l∗
(
Φ
(
min
(
q
√
x
n− 2 ,
√
c− x−
√
n1
2
δup
))
−
Φ
(
max
(
q∗(x), −√c− x−
√
n1
2
δup
)))
· f(x)dx,
where Z =
√
n1
2 (d − δup) ∼ N(0, 1), q∗(x) = −q
√
x
n−2 −
√
n1
2 (δup − δlow)
and 0 ≤ l∗ < c∗ ≤ c is such that over the range of x ∈ [l∗, c∗],
min
(
q
√
x
n− 2 ,
√
c− x−
√
n1
2
δup
)
> max
(
q∗(x), −√c− x−
√
n1
2
δup
)
.
For the example, let δlow = −δup. Then we obtain (calculations for
n1 = 12, numbers in brackets for n1 = 24, 40, respectively):
P (tlow ≥ t1−α(n− 2), tup ≤ tα(n− 2), Q1 +Q2 ≤ c) = 0.0009 (0.0193, 0.0379),
and
P
(
tlow ≥ t1−α(n− 2), tup ≤ tα(n− 2)
∣∣ Q1 +Q2 ≤ c)
is thus
0.0009
0.5946
= 0.0015 (0.0340, 0.0687).
Finally, the unconditional rejection probability of both null hypotheses is
P (reject H01 and H02) = 0.0015+0.05·(1−0.5946) = 0.0212 (0.0410, 0.0603).
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